What is HC Wainwright’s Estimate for DYN FY2028 Earnings?

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities researchers at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for Dyne Therapeutics in a research report issued to clients and investors on Wednesday, September 30th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($1.98) for the year, down from their previous forecast of ($1.91). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.59) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ FY2029 earnings at ($0.65) EPS and FY2030 earnings at $1.03 EPS.

DYN has been the subject of a number of other research reports. JPMorgan Chase & Co. cut Dyne Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the stock from $17.00 to $10.00 in a research report on Wednesday, September 9th. TD Cowen started coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.07.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $15.82 on Friday. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -4.75 and a beta of 1.13. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics has a 1 year low of $12.33 and a 1 year high of $27.31. The business has a fifty day simple moving average of $22.70 and a 200 day simple moving average of $20.59.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33).

Insider Transactions at Dyne Therapeutics

In related news, insider Douglas Kerr sold 3,745 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.35, for a total transaction of $91,190.75. Following the transaction, the insider directly owned 163,854 shares of the company’s stock, valued at approximately $3,989,844.90. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason Rhodes sold 2,160,516 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the transaction, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. This represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,376,157 shares of company stock worth $83,290,469 in the last ninety days. Insiders own 9.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC bought a new position in shares of Dyne Therapeutics in the second quarter valued at approximately $300,000. Nykredit A S purchased a new stake in Dyne Therapeutics in the second quarter worth $113,000. Moore Capital Management LP increased its stake in shares of Dyne Therapeutics by 288.2% in the second quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock worth $6,792,000 after purchasing an additional 227,029 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Dyne Therapeutics during the 2nd quarter valued at $222,000. Finally, Alyeska Investment Group L.P. purchased a new position in Dyne Therapeutics during the 2nd quarter valued at about $5,448,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Key Headlines Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Encouraging one-year DM1 data: Dyne reported that DYNE-101, also known as z-basivarsen, continued to show functional improvements after one year in its DM1 study. The results support the potential durability of the company’s targeted delivery platform and helped drive buying interest in the shares. Dyne Reports One-Year DM1 Trial Improvements
• Positive Sentiment: Analysts remain bullish: Chardan Capital reaffirmed its “buy” rating and set a $38 price target, while HC Wainwright maintained a “buy” rating despite lowering its target to $32 from $50. The targets imply substantial upside if Dyne’s clinical programs meet expectations. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Positive data may be partly reflected in the stock: Reports described the DM1 results as a reason for shares to rise, but investors are likely seeking additional evidence on the size, durability and safety of the treatment benefit before assigning a higher valuation. Dyne Therapeutics stock rises on positive DM1 trial results
• Negative Sentiment: Competitive pressure remains the main risk: A rival’s DM1 data contributed to Dyne’s recent decline, raising questions about the company’s competitive position and making a “buy-the-dip” strategy speculative rather than low risk. HC Wainwright’s target reduction also reflects more cautious expectations. Dyne Recent Price Drop on Rival’s DM1 Data

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.